These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 122593)

  • 1. Study of the immunogenicity of the Pseudomonas aeruginosa polyvalent corpuscular vaccine in human volunteers.
    Meitert E; Meitert T; Petrovici M; Sima F; Savulian C; Mitrică N; Georgescu C; Costache G
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):309-16. PubMed ID: 122593
    [No Abstract]   [Full Text] [Related]  

  • 2. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
    Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
    Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 4. [Production and experimental testing of the polyvalency of corpuscular vaccine for the prevention of Pseudomonas aeruginosa infections II. Experimental testing of the immunogenicity of polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Moroz AF; Antsiferova NG; Radkevich SA; Mishina VS
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):74-80. PubMed ID: 6800165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
    Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 7. [Isolation and study of the properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine. An evaluation of the biological properties of a polyvalent corpuscular Pseudomonas aeruginosa vaccine].
    Ttitova TI; Grigor'ev NI; Antsiferova NG; Radkevich SA; Moroz AF
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):14-8. PubMed ID: 3931392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
    Moroz AF; Kharitonova AM; Chanturiia TsK
    Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical use of a Soviet polyvalent corpuscular pyocyanic vaccine for the prevention of Pseudomonas aeruginosa infection in thermal burn victims].
    Gerasimova LI; Moroz AF; Radkevich SA; Sveshnikov AI; Mizikin EV
    Khirurgiia (Mosk); 1980 Nov; (11):36-41. PubMed ID: 6777578
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
    Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
    J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monovalent Pseudomonas aeruginosa vaccines in the treatment of otolaryngeal infections with Pseudomonas aeruginosa.
    Cincă D; Meitert E; Tomescu E; Meitert T; Suciu M; Sima F; Savulian C; Midan F; Lică I
    Arch Roum Pathol Exp Microbiol; 1982; 41(3):277-84. PubMed ID: 6818930
    [No Abstract]   [Full Text] [Related]  

  • 12. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficiency of specific immunization with corpuscular vaccines in the treatment and prophylaxis of Pseudomonas aeruginosa infections of the bones.
    Denischi A; Meitert E; Cursaru A; Purghel E; Stăngulescu D; Sima F; Savulian C; Chersulick E; Petrescu AM; Costin M
    Arch Roum Pathol Exp Microbiol; 1987; 46(2):111-27. PubMed ID: 3138966
    [No Abstract]   [Full Text] [Related]  

  • 14. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of a polyvalent vaccine against Pseudomonas aeruginosa in severely burned patients].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1984 Apr; 39(17):557-61. PubMed ID: 6435103
    [No Abstract]   [Full Text] [Related]  

  • 16. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of polyvalent vaccine against Pseudomonas aeruginosa in extensive burns].
    Nasiłowski W; Zietkiewicz W; Brudzyńska-Charewicz S; Bukowska D; Serafińska D; Rudowski W
    Pol Tyg Lek; 1981 Aug; 36(32):1207-11. PubMed ID: 6798556
    [No Abstract]   [Full Text] [Related]  

  • 18. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
    Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of polyvalent anti-Pseudomonas aeruginosa vaccine in phagocytic reaction.
    Grzybek-Hryncewicz K; Gościniak G
    Arch Immunol Ther Exp (Warsz); 1990; 38(3-4):291-7. PubMed ID: 2129384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.